At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 36 enrolled
Drug / intervention
LY3337641 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Single- and Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3337641 in Japanese and Caucasian Healthy Subjects
In Brief
A Phase 1 clinical trial evaluating LY3337641 and Placebo for Healthy. Completed, enrolled 36 participants across 1 site.
Detailed Summary
The main purpose of this study is to evaluate the safety and tolerability of LY3337641 in healthy Japanese and Caucasian participants. The study will also investigate how the body processes LY3337641 and the effect of LY3337641 on the body. The study will last up to 4 weeks for each participant. Screening may occur within 28 days prior to first dose of study drug.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
2017201820192020202120222023202420252026
Enrollment StartMar 2017
First PostedMar 2017
Primary CompletionMay 2017
TodayJul 2026
First PostedMar 20, 2017
Enrollment StartMar 15, 2017
Primary CompletionMay 25, 2017
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 9.3 years ago
Interventions
LY3337641drug
Administered orally.
Placebodrug
Administered orally.